|
|
||||||||
Papers In Press, published online ahead of print December 1, 2002
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Lipid and Diabetes Research Center, Saint Luke's Hospital, Kasnas City, MO 64111
Corresponding Author: wharris{at}saint-lukes.org
Omega-3 fatty acids (FA) reduce postprandial triacylglycerol (TG) concentrations. This study was undertaken to determine whether this effect was due to reduced production or increased clearance of chylomicrons. Healthy subjects (n=33) began with a 4-week, olive oil placebo (4 g/d) run-in period. After a 4-week wash-out period, subjects were randomized to supplementation with 4 g/d of ethyl esters of either safflower oil (SAF), eicosapentaenoic acid (EPA) or docosahexaenoic acid (DHA) group for 4 weeks. Results for EPA and DHA were similar and therefore the data were combined into one
Revised on November 8, 2002
Accepted on November 22, 2002
Omega-3 fatty acid supplementation accelerates chylomicron triglyceride clearance
-3 FA group. Omega-3 FA supplementation reduced the postprandial TG, and apo B48 and B100 concentrations by 16% (p=0.08), 28% (p<0.001) and 24% (p<0.01), respectively. Chylomicron TG half-lives in the fed state were reduced after
-3 FA treatment (6.0 +/- 0.5 vs. 5.1 +/- 0.4 min; p<0.05), but not after SAF (6.9 +/- 0.7 vs. 7.1 +/- 0.7 min). Omega-3 FA supplementation decreased chylomicron particle sizes (mean diameter; 293 +/- 44 vs. 175 +/- 25 nm; p<0.01) and increased pre-heparin lipoprotein lipase (LpL; 0.6 +/- 0.1 vs. 0.9 +/- 0.1
mol/h/mL; p<0.05) activity during the fed state, but had no effect on post-heparin LpL or hepatic lipase activities. The results suggest that
-3 FA supplementation accelerates chylomicron TG clearance by increasing LpL activity, and that EPA and DHA are equally effective.
![]()
CiteULike
Complore
Connotea
Del.icio.us
Digg
Reddit
Technorati What's this?
This article has been cited by other articles:
![]() |
M. Svensson, E. B. Schmidt, K. A. Jorgensen, and J. H. Christensen The effect of n-3 fatty acids on lipids and lipoproteins in patients treated with chronic haemodialysis: a randomized placebo-controlled intervention study Nephrol. Dial. Transplant., September 1, 2008; 23(9): 2918 - 2924. [Abstract] [Full Text] [PDF] |
||||
![]() |
I. J. Edwards, H. Sun, Y. Hu, I. M. Berquin, J. T. O'Flaherty, J. M. Cline, L. L. Rudel, and Y. Q. Chen In Vivo and in Vitro Regulation of Syndecan 1 in Prostate Cells by n-3 Polyunsaturated Fatty Acids J. Biol. Chem., June 27, 2008; 283(26): 18441 - 18449. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Sun, I. M. Berquin, R. T. Owens, J. T. O'Flaherty, and I. J. Edwards Peroxisome Proliferator-Activated Receptor {gamma}-Mediated Up-regulation of Syndecan-1 by n-3 Fatty Acids Promotes Apoptosis of Human Breast Cancer Cells Cancer Res., April 15, 2008; 68(8): 2912 - 2919. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. H. O'Keefe, N. M. Gheewala, and J. O. O'Keefe Dietary Strategies for Improving Post-Prandial Glucose, Lipids, Inflammation, and Cardiovascular Health J. Am. Coll. Cardiol., January 22, 2008; 51(3): 249 - 255. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Lopez, B. Bermudez, Y. M. Pacheco, G. Lopez-Lluch, W. Moreda, J. Villar, R. Abia, and F. J. G. Muriana Dietary Oleic and Palmitic Acids Modulate the Ratio of Triacylglycerols to Cholesterol in Postprandial Triacylglycerol-Rich Lipoproteins in Men and Cell Viability and Cycling in Human Monocytes J. Nutr., September 1, 2007; 137(9): 1999 - 2005. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. S Kelley, D. Siegel, M. Vemuri, and B. E Mackey Docosahexaenoic acid supplementation improves fasting and postprandial lipid profiles in hypertriglyceridemic men Am. J. Clinical Nutrition, August 1, 2007; 86(2): 324 - 333. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Vanschoonbeek, M. A. H. Feijge, W. H. M. Saris, M. P. M. de Maat, and J. W. M. Heemskerk Plasma Triacylglycerol and Coagulation Factor Concentrations Predict the Anticoagulant Effect of Dietary Fish Oil in Overweight Subjects J. Nutr., January 1, 2007; 137(1): 7 - 13. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. K Nies, A. A Cymbala, S. L Kasten, D. G Lamprecht, and K. L Olson Complementary and Alternative Therapies for the Management of Dyslipidemia Ann. Pharmacother., November 1, 2006; 40(11): 1984 - 1992. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. H. Lichtenstein Thematic review series: Patient-Oriented Research. Dietary fat, carbohydrate, and protein: effects on plasma lipoprotein patterns J. Lipid Res., August 1, 2006; 47(8): 1661 - 1667. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. P. Oliva, L. Pisciotta, G. L. Volti, M. P. Sambataro, A. Cantafora, A. Bellocchio, A. Catapano, P. Tarugi, S. Bertolini, and S. Calandra Inherited Apolipoprotein A-V Deficiency in Severe Hypertriglyceridemia Arterioscler. Thromb. Vasc. Biol., February 1, 2005; 25(2): 411 - 417. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. A. Turvey, G. J. F. Heigenhauser, M. Parolin, and S. J. Peters Elevated n-3 fatty acids in a high-fat diet attenuate the increase in PDH kinase activity but not PDH activity in human skeletal muscle J Appl Physiol, January 1, 2005; 98(1): 350 - 355. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Park, P. G Jones, and W. S Harris Triacylglycerol-rich lipoprotein margination: a potential surrogate for whole-body lipoprotein lipase activity and effects of eicosapentaenoic and docosahexaenoic acids Am. J. Clinical Nutrition, July 1, 2004; 80(1): 45 - 50. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. A. Turvey, G. J. F. Heigenhauser, M. Parolin, and S. J. Peters Elevated n-3 fatty acids in a high-fat diet attenuate the increase in PDH kinase activity but not PDH activity in human skeletal muscle J Appl Physiol, January 1, 2005; 98(1): 350 - 355. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH |
| All ASBMB Journals | Journal of Biological Chemistry |
| Molecular and Cellular Proteomics | ASBMB Today |